A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
From MaRDI portal
Publication:6572291
DOI10.1002/BIMJ.202200288zbMATH Open1541.62302MaRDI QIDQ6572291
Publication date: 15 July 2024
Published in: Biometrical Journal (Search for Journal in Brave)
Cites Work
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Number of patients per cohort and sample size considerations using dose escalation with overdose control
- A New Dose‐Finding Design for Bivariate Outcomes
- A Bayesian Phase I/II Trial Design for Immunotherapy
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
- An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
- Bayesian leveraging of historical control data for a clinical trial with time-to-event endpoint
- General classes of multiple binary regression models in dose finding problems for combination therapies
- A Bayesian dose finding design for oncology clinical trials of combinational biological agents
- Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents
- AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials
- Combining cytotoxic agents with continuous dose levels in seamless phase I--II clinical trials
This page was built for publication: A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6572291)
